European CHMP recommends approval of vosoritide (Voxzogo) for treatment of achondroplasia in patients aged 2 years

Vosoritide is a modified type C natriuretic peptide which promotes endochondral bone growth by promoting chondrocyte proliferation and differentiation. It is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed.

European Medicines Agency